Eisai commitment to Oncology
Eisai's hhc (human health care) mission is to give first thoughts to patients and their families by developing drugs for diseases with significant unmet medical need. Nowhere is this more compelling than in oncology, one of Eisai's long-standing therapeutic areas of focus since 1987.
Eisai is committed to enhancing its commercial oncology infrastructure. The organization is well positioned to market new oncology products that originate from Eisai's research and discovery efforts or through future acquisition, co-promotion or in-licensing opportunities.
Eisai is committed to ongoing research in oncology. We continually build upon our extensive scientific expertise in this area to provide those affected with treatments and solutions that may help. This effort is supported by our global capability to conduct discovery and preclinical research, and develop small molecules, therapeutic vaccines, and biologic and supportive care agents for cancer across multiple indications.